Urogen Pharma (NASDAQ:URGN – Get Free Report) reached a new 52-week high during trading on Wednesday . The stock traded as high as $33.31 and last traded at $32.6690, with a volume of 51651 shares traded. The stock had previously closed at $31.95.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently weighed in on the stock. LADENBURG THALM/SH SH started coverage on shares of Urogen Pharma in a research note on Monday, May 11th. They issued a “buy” rating and a $43.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Urogen Pharma in a research note on Monday, April 20th. Oppenheimer reissued an “outperform” rating on shares of Urogen Pharma in a research report on Tuesday, June 2nd. HC Wainwright reissued a “buy” rating and issued a $45.00 price objective on shares of Urogen Pharma in a research note on Wednesday, June 3rd. Finally, D. Boral Capital restated a “buy” rating and set a $33.00 target price on shares of Urogen Pharma in a research report on Tuesday, March 31st. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $39.50.
View Our Latest Report on Urogen Pharma
Urogen Pharma Stock Performance
Urogen Pharma (NASDAQ:URGN – Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.01. The company had revenue of $50.96 million during the quarter, compared to the consensus estimate of $44.83 million. Analysts expect that Urogen Pharma will post -0.98 EPS for the current fiscal year.
Insider Transactions at Urogen Pharma
In other Urogen Pharma news, insider Mark Schoenberg sold 5,222 shares of the firm’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $27.30, for a total transaction of $142,560.60. Following the transaction, the insider directly owned 139,763 shares in the company, valued at $3,815,529.90. This trade represents a 3.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 4.80% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Urogen Pharma
Several institutional investors have recently made changes to their positions in the company. Paradigm Biocapital Advisors LP bought a new stake in shares of Urogen Pharma in the 3rd quarter valued at about $84,111,000. Soleus Capital Management L.P. bought a new position in shares of Urogen Pharma during the second quarter valued at approximately $29,934,000. Healthcare of Ontario Pension Plan Trust Fund bought a new position in shares of Urogen Pharma during the fourth quarter valued at approximately $26,350,000. MPM Bioimpact LLC increased its holdings in Urogen Pharma by 597.3% during the fourth quarter. MPM Bioimpact LLC now owns 941,378 shares of the company’s stock valued at $22,047,000 after buying an additional 806,378 shares during the period. Finally, TCG Crossover Management LLC purchased a new position in Urogen Pharma during the third quarter valued at approximately $14,311,000. Hedge funds and other institutional investors own 91.29% of the company’s stock.
Urogen Pharma Company Profile
UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.
The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.
Featured Stories
- Five stocks we like better than Urogen Pharma
- Microsoft’s Xbox Problem Is Bigger Than a Console War
- Dave & Buster’s Q1 Miss Raises the Stakes for Its Turnaround Plan
- Flying Under the Radar: Lockheed Martin’s $2.8B Stealth Setup
- Bread’s Comeback Is Real—But Is the Easy Money Gone?
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
